Therapeutic potency of compound RMY-205 for pulmonary fibrosis induced by SARS-CoV-2 nucleocapsid protein

• Published in: Cell chemical biology Vol. 30; no. 3; pp. 261 - 277.e8
• Main Authors: Zhang, Zhi-yuan, Ju, Cui-yu, Wu, Liu-zheng, Yan, Han, Hong, Wen-bin, Chen, Hang-zi, Yang, Peng-bo, Wang, Bao-Rui, Gou, Tong, Chen, Xiao-yan, Jiang, Zhi-hong, Wang, Wei-jia, Lin, Tianwei, Li, Fu-nan, Wu, Qiao
• Format: Journal Article
• Language: English
• Published: United States Elsevier Ltd 16.03.2023
• Subjects: Animals; compound RMY-205; COVID-19 - complications; Fibrosis; Mice; N protein; Nucleocapsid Proteins - therapeutic use; pulmonary fibrosis; Pulmonary Fibrosis - complications; Pulmonary Fibrosis - drug therapy; SARS-CoV-2; TGF-β/Smad pathway; SARS-CoV-2; compound RMY-205; N protein; pulmonary fibrosis; TGF-β/Smad pathway

Pulmonary fibrosis is a typical sequela of coronavirus disease 2019 (COVID-19), which is linked with a poor prognosis for COVID-19 patients. However, the underlying mechanism of pulmonary fibrosis induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unclear. Here, we demonstrat...